The Blanket Purchase Agreement will expedite the purchasing process for groups within the National Institutes of Health.
IRVINE, Calif., June 24 /PRNewswire-FirstCall/ -- ChromaDex Corp., (OTC Bulletin Board: CDXC) a leader in phytochemical reference standards and contract research, announced today that the National Institutes of Health established a Blanket Purchase Agreement (BPA) with the Company. The Agreement covers all products and services offered by ChromaDex. This includes botanical reference materials, phytochemicals, bulk chemical production, analytical testing services, analytical method development, contract research, isolation of compounds, chemical synthesis and natural product libraries.
The BPA makes it easier for the various Institutes within NIH to do business with ChromaDex.
"We are honored to be recognized by the National Institutes of Health with the issuance of a Blanket Purchase Agreement to ChromaDex," said Frank Jaksch, co-founder and CEO of ChromaDex. "There is considerable work taking place at NIH in the areas of natural products, dietary supplements and alternative medicines. As a leader in this field, ChromaDex will be working closely with NIH to provide products and services to support their efforts."
About National Institutes of Health
NIH is the steward of medical and behavioral research for the Nation. Its mission is science in pursuit of fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to extend healthy life and reduce the burdens of illness and disability. Composed of 27 Institutes and Centers, the NIH provides leadership and financial support to researchers in every state and throughout the world. For over a century, the National Institutes of Health has played an important role in improving the health of the nation.
ChromaDex is a world leader in the development of Phytochemical and Botanical Reference Standards and the creation of associated intellectual property. ChromaDex is committed to sustainable "Green chemistry" and provides the dietary supplement, food, beverage, nutraceutical and cosmetic industries with the analytical tools and services to meet product regulatory, quality, efficacy and safety standards.
Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to ability to market, produce and sell the referenced ingredients, risks relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
|SOURCE ChromaDex Corp.|
Copyright©2009 PR Newswire.
All rights reserved